DFTX Q3 2024 Earnings — Definium Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

DFTXDefinium Therapeutics, Inc.

$2B

Q3 2024 Earnings

Healthcare Medical - Pharmaceuticals

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$25M

Net Income

-$14M

EPS (Diluted)

$-0.17

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$17M

Free Cash Flow

-$17M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$320M

Total Liabilities

$58M

Stockholders' Equity

$262M

Cash & Equivalents

$295M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$25M	-$22M	-14.7%
Net Income	-$14M	-$18M	+23.7%